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Abstract
The Cancer Genome Atlas (TCGA) network study of 12 cancer types (PanCancer 12) revealed 
frequent mutation of TP53, and amplification and expression of related TP63 isoform ΔNp63 in 
squamous cancers. Further, aberrant expression of inflammatory genes and TP53/p63/p73 targets 
were detected in the PanCancer 12 project, reminiscent of gene programs co-modulated by cREL/
ΔNp63/TAp73 transcription factors we uncovered in head and neck squamous cell carcinomas 
(HNSCC). However, how inflammatory gene signatures and cREL/p63/p73 targets are co-
modulated genome-wide is unclear. Here, we examined how inflammatory factor TNF-α broadly 
modulates redistribution of cREL with ΔNp63α/TAp73 complexes and signatures genome-wide in 
the HNSCC model UM-SCC46 using chromatin immunoprecipitation sequencing (ChIP-seq). 
TNF-α enhanced genome-wide co-occupancy of cREL with ΔNp63α on TP53/p63 sites, while 
unexpectedly promoting redistribution of TAp73 from TP53 to Activator Protein-1 (AP-1) sites. 
cREL, ΔNp63α, and TAp73 binding and oligomerization on NF-κB, TP53 or AP-1 specific 
sequences were independently validated by ChIP-qPCR, oligonucleotide-binding assays, and 
analytical ultracentrifugation. Function of the binding activity was confirmed using TP53, AP-1, 
and NF-κB specific response elements, or p21, SERPINE1, and IL-6 promoter luciferase reporter 
activities. Concurrently, TNF-α regulated a broad gene network with co-binding activities for 
cREL, ΔNp63α, and TAp73 observed upon array profiling and RT-PCR. Overlapping target gene 
signatures were observed in squamous cancer subsets and in inflamed skin of transgenic mice 
overexpressing ΔNp63α. Furthermore, multiple target genes identified in this study were linked to 
TP63 and TP73 activity and increased gene expression in large squamous cancer samples from 
PanCancer 12 TCGA by CircleMap. PARADIGM inferred pathway analysis revealed the network 
connection of TP63 and NF-κB complexes through an AP-1 hub, further supporting our findings. 
Thus, inflammatory cytokine TNF-α mediates genome-wide redistribution of the cREL/p63/p73, 
and AP-1 interactome, to diminish TAp73 tumor suppressor function and reciprocally activate NF-
κB and AP-1 gene programs implicated in malignancy.
Keywords
TNF-alpha; cRel; ΔNp63α; TAp73; ChIP-seq
Introduction
The Cancer Genome Atlas (TCGA) project aims to provide a comprehensive catalog of the 
key genomic changes in major cancer types, in order to foster effective diagnosis, treatment 
and prevention. The recently published TCGA HNSCC (head and neck squamous cell 
carcinoma) project, including 279 patient tissues, revealed that more than 84% of HPV 
negative HNSCC harbor genetic alterations in tumor suppressor TP53, concurrent with 
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amplification and expression of related family member ΔNp63 in ~47% cases, and altered 
TNF-α-NF-κB/REL, inflammation, and death pathways in ~60% cases (1). In addition, the 
TCGA network PanCancer 12 project performed integrative analyses on 3,527 specimens of 
12 cancer types, using five genome-wide high throughput platforms (2). The project revealed 
a unique convergence that classified squamous cell carcinoma (SCC) of head and neck, lung 
and a subset of bladder cancers into a common subtype, called “squamous-like” (2). This 
genomic classification suggests that those squamous cancer types shared more molecular 
similarities than other tumor types from the same tissue-of-origin. Consistent with findings 
in the HNSCC TCGA project, the hallmarks of these squamous cancers include high rates of 
TP53 mutation, amplification and over-expression of oncogenic isoform ΔNp63, and altered 
activation of TP53/TP63/TP73 and immune pathway genes linked to NF-κB/REL 
transcription factors. These newly identified SCC signatures raised several critical questions, 
including how and to what extent do TP63/TP73 and NF-κB/REL family transcription 
factors interact to regulate global gene programs in squamous cancers?
The TP53 family comprises TP53, TP63, and TP73 and their isoforms. TP53 is the most 
frequently mutated tumor suppressor gene in cancer, especially in squamous cancers, and is 
described as the “guardian of the genome.” Mutation or inactivation of TP53 promotes 
genomic instability by disrupting cell cycle arrest, DNA repair, senescence, apoptosis, and 
autophagy of irreversibly damaged cells (3). Interestingly, however, the other TP53 family 
members, TP63 and TP73, are infrequently mutated, and can potentially compensate for 
disrupted TP53 (4, 5), but their shared and distinct functions appear to be more complex 
than those of TP53 in tumorigenesis, as suggested by TCGA findings. TP63 and TP73 
isoforms share a core structural architecture, sequence homology, and potential but usually 
weaker tumor suppressor function than TP53, while they also exhibit distinct roles in 
development, adhesion, tumor promotion, and inflammatory responses in normal and 
malignant epithelia (4, 6-8). The TA isoforms contain full-length N-terminal transactivating 
domains that function as TP53 homologs, whereas ΔN isoforms having a truncated N-
terminus can serve as antagonists of TP53 and its TA counterparts, as well as promote 
cancer gene programs (9, 10). However, the genome-wide role and mechanisms whereby 
ΔNp63α/TAp73 promote tumorigenesis and linked to inflammation in cancer are undefined.
We recently revealed that inflammatory cytokine TNF-α stimulates binding of NF-κB 
subunit cREL with ΔNp63 to form a protein complex and displacement of TAp73 DNA 
binding, leading to the repression of growth arrest and apoptotic genes CDKN1A (p21), 
NOXA, and PUMA (6). Complexes between cREL, RELA and ΔNp63 were also implicated 
in reciprocal activation of several NF-κB regulated genes (8). Interestingly, the NF-κB 
family proto-oncogene cREL is amplified and overexpressed in a subset of HNSCC and 
other cancers (11), but its functions are less well characterized (12). These experimental data 
suggest the hypothesis that NF-κB and TP53 family members could coordinate wider global 
and reciprocal cross-talk between cell death, survival and inflammatory gene programs. 
Specifically, are these interactions between cREL, ΔNp63α and TAp73 part of a novel 
mechanism that reciprocally regulates a genome-wide oncogenic program? Do the reciprocal 
interactions between cREL and ΔNp63α with TAp73 indicate their capability to bind TP53, 
NF-κB or other DNA response elements (REs)? Finally, what is the fate and functional 
significance of TAp73 displaced by the cREL/ΔNp63α complexes?
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To answer these questions, we performed genome-wide chromatin immunoprecipitation 
assays, followed by high-throughput sequencing (ChIP-seq), and microarray profiling in 
HNSCC cell lines, to explore the genome-wide regulatory role of cREL/ΔNp63α and TAp73 
complexes. Furthermore, bioinformatic analysis of in vivo data from TCGA, 
immunohistochemistry and tissue array of HNSCC, and a ΔNp63α transgenic mouse model 
supports their contribution in the regulation of the cancer gene program. These findings 
present a new paradigm for how TNF-α and these TFs orchestrate gene programs implicated 
in cancer-related inflammation, survival, and migration, and help explain the mechanisms 
underpinning the dysregulated network of TP53/TP63 and inflammation observed in the 
Pan-TCGA project.
Results
TNF-α promotes enrichment and co-localized binding of cREL, TP63α and TAp73 in the 
regulatory regions and around transcription start sites genome-wide
To investigate cREL, p63α and TAp73 binding activity genome-wide, ChIP-seq was 
performed using UM-SCC46 cells, previously shown to exhibit higher expression of 
mtTP53, TP63 and TP73 proteins, and TNF-α modulation of their interactions in target gene 
regulation representative of HNSCC with mtTP53 (6). We confirmed that TNF-α induced 
cREL and ΔNp63α, and partially decreased multiple TAp73 isoforms in nuclear extracts 
(Figure 1A), where TAp73 is predominantly detected in UM-SCC46 and other HNSCC lines 
under baseline conditions (Figure S1A). TNF-α increased total genomic binding peak 
numbers and peak associated genes by cREL and p63α, while partially decreasing TAp73 
binding activity (Figure 1B, Table S1), and similar patterns were seen on individual 
chromosomes (Figure S1B, S2). We observed that the percentage of genome-wide bindings 
were disproportionately enriched near or within genes (promoter, intragenic, transcriptional 
termination site region) compared with much larger intergenic regions (Figure 1C, upper 
panels). Cumulatively, over half of the binding peaks were within the promoter (~7-12%) 
and intragenic regions (35-41%). These peri-genic region peak distributions were 
significantly enriched compared with the whole genome background distribution, tested 
using the exact binomial test (Figure S3). The binding activities within the intragenic regions 
were enriched in the first intron (Figure 1C, lower panels). After TNF-α treatment, cREL 
and p63α binding were substantially induced near the TSSs, while the basal TAp73 TSS 
binding peak did not appreciably change in the presence of TNF-α (Figure 1D). The 
intersection sets of three TF binding peaks within 1 kb distance were identified, showing 
that intersecting binding peaks under basal conditions (215) were significantly increased 
after TNF-α treatment (1159) (Figure 1E, upper and lower left; Fisher's exact test, 
p=2.2e-16). 793 TAp73 basal binding peaks intersected with TNF-induced cREL and p63α 
binding (Figure 1E, lower right). After combination of all binding activities, 1,217 candidate 
binding peaks were observed, which aligned within the regulatory loci of genes and 
generated 530 genes that displayed co-binding by the three TFs (Figure S4). Furthermore, 
the physical distance between the intersections of three TF binding peaks was examined, 
defined as within 1kb distance on the same chromosome (Figure 1F). TNF-α increased 
intersection binding peaks between cREL and p63α, or between p63α and TAp73, around 
the TSS within <200 bp (Figure 1F, upper two panels), when compared with other 
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intersections (Figure 1F, lower panels). More detailed results were included in the 
supplemental information. Together, these data show that TNF-α modulated the co-
localization of cREL, p63α, and TAp73 binding enriched around TSSs.
De novo motif search defines genome-wide binding on TP53 and AP-1 consensus 
elements modulated by TNF-α
Next, the top motifs most frequently bound by the three TFs under different treatment 
conditions were identified using Gibb's motif sampler and summarized (Figure 2A-D, Figure 
S5). The basal binding of TAp73 (Figure 2A, left), and TNF-α induced p63α binding 
(Figure 2B, left), were enriched for a TP53/p63 consensus sequence. Surprisingly, basal 
cREL (Figure 2C, left) and TNF-α induced TAp73 bindings (D, left) were enriched for AP-1 
consensus motifs. A narrow distribution of ~200 bp for the basal TAp73 (Figure 2A, right) 
and TNF-α induced p63α binding to TP53 motifs (Figure 2B, right) were observed. 
However, broader distribution patterns (~400 bp) were observed for the basal and TNF-α 
induced cREL (Figure 2C, right and Figure S5), and TNF-α induced TAp73 binding on 
AP-1 sites (Figure 2D, right). On TP53/p63 motifs, there was abundant overlapping binding 
activity of basal TAp73 versus TNF-α induced p63α, ranging within ~200-300 bp (Figure 
2E, left). TNF-α also induced concurrent binding of p63α on TP53 sites and TAp73 on 
AP-1 motifs, located in a broader range of ~400 bp (Figure 2E, right).
Binding of purified cREL homology domain and TP73 DNA-binding domain to cREL, TP53 
and AP-1 response elements (REs)
Next, we purified recombinant cREL Rel homology domain (RHD) and TP73 DNA binding 
domain (DBD) proteins and tested their ability to bind oligonucleotides with minimal 
consensus sequences from cREL, TP53 and AP-1 response elements (REs) (Figure 2F). 
Analytical ultracentrifugation with fluorescein-labeled DNA allowed us to measure 
sedimentation velocities of the protein-DNA complexes and classify their oligomerization 
state. Remarkably, cREL exhibited binding activities for all three REs, with a higher affinity 
for its own RE (Figure 2F, left). TP73 DBD exhibited dimeric DNA-protein complexes for 
all three REs tested; however, the tetramer complex was only observed for the TP53 RE 
(Figure 2F, right). Thus, our binding experiments with purified proteins confirmed that both 
cREL RHD and p73 DBD are able to bind not only to their own consensus sequences, but 
also to the other DNA REs, supporting the binding to motifs identified in the ChIP-seq 
experiment.
Validation of co-localized binding on individual gene promoters by ChIP-qPCR and oligo-
based binding assays
Representative peak binding activities of four of the genes detected by ChIP-seq are 
presented in Figure S6. We further validated the specific binding activities of the three TFs 
on regulatory regions of eight representative genes detected by ChIP-seq and confirmed the 
binding by ChIP-PCR (Figure 3A-C, Table S2). Treatment with TNF-α significantly 
increased cREL and/or p63α binding (Figure 3A, B), while TAp73 binding was partially 
decreased or not significantly changed (Figure 3C). Next, we performed a different binding 
experiment using short ~50-70 bp synthetic oligonucleotides containing 10-20bp sequences 
of individual or a combination of predicted consensus motifs (Figure 3D, Table S3). We 
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observed a relatively stronger basal TAp73 binding activity when compared with p63α 
binding, consistent with the ChIP-seq and ChIP-qPCR results. Interestingly, the 
oligonucleotide containing a predicted AP-1 motif (p21-c) without the other motifs also 
exhibited TAp73 binding. These binding activities detected by ChIP-seq were validated by 
two different experimental methods. Thus our current study provided evidence for the co-
localization of cREL, ΔNp63 and TAp73 to multiple target promoters and response elements 
in response to TNF-α, consistent with our previous publications (6, 8).
cREL, ΔNp63α, and TAp73 modulate transcriptional regulation and gene expression
Next, we performed functional validation using luciferase reporters containing p53, AP1 and 
NF-κB/REL specific consensus REs after expression of ΔNp63α, TAp73, cREL or empty 
control vectors (Figure 4A). Overexpressed TAp73 was a strong inducer of classical TP53 
RE reporter activity, which was down-modulated by TNF-α (Figure 4A, upper left). Both 
ΔNp63α and TAp73 also induced significant AP-1 RE inducing activity, and TNF-α further 
enhanced it (upper middle). cREL induced strong NF-κB reporter activity that was increased 
by TNF-α, while ΔNp63α and TAp73 exhibited less pronounced effects (upper right). Then 
the individual promoters of CDKN1A (p21) containing TP53, p63 REs, SERPINE1 with 
AP-1 RE, and IL-6 with AP-1 and NF-κB REs were tested for their activities (Figure 4A, 
lower panels). TAp73 was the strongest inducer of CDKN1A (p21) and SERPINE1. 
ΔNp63α was the strongest inducer of IL-6, while mutation of either the NF-κB or the AP-1 
RE significantly suppressed the activity. Together, these data further confirm the overlapping 
capability of these TFs to modulate p53, AP1 and NF-κB/REL transcriptional activities.
We examined how TNF-α and three TFs modulated expression of 6 candidate genes 
identified through ChIP-seq and confirmed by microarray (Figure 5 below and Figure S6, 
S7). ΔNp63α and TAp73 strongly induced GADD45A, a known TP53 target (13), as well as 
AP-1 subunit FOSL1 and SERPINE1 (Figure 4B, upper panels). CEBPA was strongly 
repressed by ΔNp63α and TAp73 (Figure 4B, lower left panel). The modulation of 
MAP4K4 and CFLAR (FLIP) by the three TFs was distinct, in that cREL plus TNF-α, 
ΔNp63α alone, and ΔNp63α plus TNF-α significantly induced gene expression. 
Collectively, TNF-α-modulated cREL, ΔNp63α, and TAp73 can differentially regulate a 
functionally diverse gene repertoire.
TNF-α globally modulates expression of genes with co-localized binding of TFs
Next we tested if TNF-α globally modulates expression of genes exhibiting co-localized 
binding of cREL, p63α, and TAp73 (Figure 5). A total of 1,050 genes with ≥1.5 fold 
differential expression were identified during at least one time point after TNF-α treatment. 
Without TNF-α, a quarter of altered genes exhibited TF binding, while TNF-α significantly 
increased up- and down-regulated genes bound by the TFs by ~10%, together accounting for 
a third of differentially expressed genes (Figure 5A, B, colored sections). TNF-α treatment 
significantly altered gene numbers with binding activities (Chi-square, up-regulated genes, 
p=4.3E-07; down-regulated genes, p=5.5E-05). The numbers of differentially expressed 
genes with individual or overlapping binding activities for the three TFs are presented for 
basal activities (Figure 5C), or TNF-α modulated activities (Figure 5D). From these, we 
identified those genes displaying co-binding of all three transcription factors that were up- or 
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down-regulated by TNF-α from Figure 5C, D, and removed the redundant genes. 
Altogether, TNF-α up-regulated 46 genes and down-regulated 27 genes with overlapping 
binding of cREL, p63α, and TAp73, which were selected for hierarchical gene clustering 
and displayed in heatmaps (Figure 5E). Supporting the potential for bidirectional gene 
modulation, the expression of a selection of target genes up- and down-modulated by TNF-α 
treatment was validated by qRT-PCR (Figure S7). Using a less stringent difference of 1.3 
fold change in gene expression by TNF-α treatment, we detected 84 up-regulated genes and 
61 down-regulated genes bound by all three transcription factors (Table S4a and 4b). Using 
either 1.5 or 1.3-fold criteria, the TNF-α modulated genes bound by the TFs include 
multiple molecules implicated in inflammation, oncogenesis, and NF-κB and AP-1 mediated 
signaling.
cREL, ΔNp63, and TAp73 expression and altered gene and protein signatures in HNSCC 
tissues and ΔNp63α transgenic mouse skin
We examined the 46 TNFα-upregulated genes and 27 down-regulated genes co-bound by all 
3 TFs from Figure 5E using the HNSCC mRNAseq expression dataset recently published for 
279 primary tumor and 16 mucosa specimens from The Cancer Genome Atlas (1). Using 
these data, we found 23/73 genes (31.5%), including 13 of 46 activated genes, and 10 of 27 
repressed genes, showed significant concordance when comparing primary HNSCC tumor to 
mucosa specimens (Figure 6A; fold change ≥1.5, p<0.05, student t-test with FDR correction 
<1% cut off). An additional 23 genes (31.5%) were also expressed in the same direction as 
in cell lines, but below the significance threshold (Table S6). Thus, overall 63% of genes 
showed consistent changes in direction of expression when comparing primary tumors to 
mucosa between cell line data and TCGA human tissue data. Consistent with this, an 
unsupervised cluster analysis and heatmap of the TCGA data for all 73 genes confirms that 
many of the TNFα inducible and down-regulated genes in cell lines co-cluster among 4 
major tumor subsets (Figure S8, clusters a-d). Among the TNF-α inducible genes, several of 
the most significantly upregulated genes co-cluster predominantly in major clusters a and/or 
b (SERPINE1, MET, SPOCK1, CRISPLD2, TINAGL1, LEPREL1, TNS3, PARP14, 
CDH3), which have previously been reported in PubMed to be deregulated in cancer and/or 
metastasis. MET and SERPINE1 are implicated in cell migration, invasion and metastasis, 
and SERPINE1 is also a downstream target of MET signaling (14-17).
As additional TP63 bound and modulated genes identified in our dataset are implicated in 
cancer, inflammation and metastasis, we also examined 48 TP63 targets, including 31 
curated from the literature, and 17 from our prior (8) or present study of TNF-α modulated 
genes (Figure S7), as described in supplemental Methods. An expression-based method was 
used to cluster a group of genes with common profiling patterns and TP63 transcription 
factor motifs, to computationally infer co-expressed networks, using three independent 
publicly available microarray data sets containing 125 HNSCC samples that include 58 non-
metastatic and 67 metastatic HNSCC tissues (18-20). Among these genes, a statistically 
significant correlation was established between expression of TP63 and 35 genes (71.4%, 
Pearson correlation coefficient p<0.05, Figure 6B). This analysis provided evidence for 
differential expression of multiple TP63-linked genes that are implicated cancer cell 
phenotype (e.g. JUNB/FOSL1, CDKN1A, JAG2/NOTCH2), invasion and metastasis (e.g., 
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SERPINE1, MET, SNAI2, MMP10), and inflammation (e.g. IL1A, IL8, RELB). Several of 
these TP63 target genes also co-modulated by TNF-α co-cluster together in major subsets of 
TCGA HNSCC tumors (Figure S8, e.g., FOSL1, CDKN1A (p21), SERPINE1, MET, 
TNFAIP8).
We further compared ΔNp63 bound and up-regulated genes in a conditional K5-ΔNp63α 
transgenic mouse model, where increased tnf-α expression and a similar nuclear 
redistribution of cREL/ΔNp63 and TAp73 was observed (21, 22). Array profiling detected 
increased expression of a panel of up-regulated genes, which were validated by qRT-PCR. 
These genes included AP-1 subunits Fosl1 and Junb, NF-κB pathway related genes Traf1, 
Ikkε and Relb, and their downstream genes, Il-6, and Serpine1 (Figure 6C).
We next validated if proteins of TNF-α co-modulated TFs and four target genes identified in 
multiple platforms above, display corresponding alterations in human HNSCC tumor and 
tissue arrays. The nuclear-cytoplasmic distribution of cREL, ΔNp63, and TAp73 in human 
specimens was quantified by immunohistochemistry score. We observed increased cREL 
and ΔNp63, and decreased TAp73 nuclear distribution, with a reciprocal decrease in 
cytoplasmic cREL and increased TAp73 cytoplasmic staining in HNSCC (Figure 6D, S9), 
consistent with TNF-α modulated nuclear redistribution and DNA binding of these TFs in 
HNSCC in vitro in Figure 1A, B, and prior studies (6) (8). Next, we examined the protein 
expression of target genes in human HNSCC tissue array, which contains 61 primary tumors 
of stage I-IV at different anatomic locations, 8 lymph node metastatic tumors and 11 normal 
mucosa tissues (Supplemental Methods). Notably, key AP-1 family transcription factor 
targets JUNB and FOSL1, showed significantly elevated nuclear staining in HNSCC tumors 
relative to mucosa (Figure 6E), consistent with altered AP-1 promoter binding and 
expression of JUNB and FOSL1 observed above (Figures 3-5). Further, the nuclear staining 
of JUNB and FOSL1 was significantly correlated when compared with cREL (Figure 6F). 
Increase in staining for two additional targets, IKKε and SERPINE1, were also significantly 
correlated with cREL and p63 staining, respectively. Together, these data from human and 
mouse tissues support our hypothesis for the altered cellular distribution and functional co-
modulation of cREL, ΔNp63α, TAp73, with AP-1 subunits JUNB/FOSL1, and a subset of 
other target genes detected in different in vitro and in vivo systems.
CircleMap and Pearson correlation analyses support TP53/p63/p73 modulated gene 
signatures in squamous cancers
We next examined how our current findings may relate to large datasets and analyses from 
the recently published TCGA PanCancer 12 project, which identified inflammatory as well 
as a “TP53-like” compensatory gene expression activity pattern associated with increased 
ΔNp63 and TP73 activities, and frequent genomic inactivation of TP53 in the squamous-like 
tumors (2). These squamous cancers included 293 HNSCC, 156 lung SCC and 24 bladder 
SCC, which were analyzed for TP53/63/73 status and expression and function of 8 genes 
identified among their known and new targets in the present study. Figure 7A shows 
CircleMaps, which enable a multi-dimensional comparison of the genomic alterations, 
expression, and inferred pathway activities for TP53, ΔNp63, TP73, and these target genes, 
using the annotated PARADIGM bioinformatics analytic platform (23, 24). The TP53 
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CircleMap shows that the majority of SCC tissues contain TP53 mutations (second circle), 
and/or copy number loss (third circle) with corresponding decrease in TP53 expression 
(fourth circle). However, they retain weak inferred PARADIGM activity for TP53 (the outer 
circle), which cannot be explained by inactivated TP53, but could be compensated by 
overlapping function of other family members. Consistent with this, the TP63 CircleMap 
exhibited high copy number gain, expression, and PARADIGM gene signatures, supporting 
a role for copy number gain and expression in TP63 PARADIGM gene activity. Similarly, 
TP73 overexpression and PARADIGM activity are also congruent. We further analyzed 
eight targets identified in this study, including genes involved in cell cycle (CDKN1A (p21), 
GADD45), signal receptor and kinase (MET, MAP4K4), transcription factors (AP-1/FOSL1, 
CEBPA), and secreted factors (SERPINE1, IL6). The expression and PARADIGM activity 
of ΔNp63, TP73, and these target genes are higher across SCC tumors compared with other 
cancer types. By Pearson correlation analysis (Figure 7B), ΔNp63 exhibited significant 
positive correlation with 5 genes bound and inducible by TNF-α, including MAP4K4, 
FOSL1, CDKN1A (p21), and GADD45, whose activation ΔNp63 and TNF-α promotes, and 
a negative correlation with CEBPA, repressed by ΔNp63 and TNF-α (Figures 4B, 5E). 
TP73 exhibited a negative association with IL6, which TAp73 suppresses, and a positive 
correlation with CDKN1A (p21), which it activates (Figure 4A). SERPINE1 showed only a 
weak negative association with TP73, which was observed with TNF-α treatment by 
reporter but not RT-PCR (Figure 4A, B).
PARADIGM SuperPathway analyses connect p63, NF-κB, and AP-1 subnetworks in 
squamous cancers
Our current and prior experimental data indicate that ΔNp63 and REL NF-κB family 
members bind and modulate inflammation and survival genes (Figures 3-5) (6, 8, 25). 
Analyses of TCGA PanCancer 12 datasets also revealed a strong TP63 gene signature 
associated with altered immune and inflammatory gene signatures in squamous cancers (2). 
However, the network(s) linking TP63 and NF-κB family members and target genes has not 
been well elucidated. We thus searched within the interconnected network of differentially 
activated PARADIGM pathways, linked through regulatory hubs with >15 downstream 
targets, derived from a larger interconnected network displaying differentially activated 
proteins inferred between the C2-Squamous-like subtype and other tumors, as detailed in 
Supplemental Methods, Table S5, Figure S10 (26). Interestingly, we observed increased 
activation of the network neighborhood surrounding TP63, connected with NF-κB complex 
(RELA/p50) through AP-1 (JUN/FOS) complexes within the squamous cancers (Figure 7C). 
The activation of these networks and targets are consistent with our evidence that TNF-α 
orchestrates cREL/ΔNp63 binding and induction of AP-1 subunits, reprograming of 
cREL/p73 binding via AP-1 binding consensus sites, and their related gene signatures in 
vitro and in vivo (Figure 2-6). Several genes shown on the network identified in this study 
have been independently validated previously, such as TP63 regulated CDKN1A, 
GADD45A, IL1A, CHUK, YAP1, IGFBP3, KRT14; as well as NF-κB and AP-1 related 
genes IL-6 and IL-8, and MAPK1/ERK/JUN/FOSand pathways. Most of these related genes 
in squamous cancers are activated (red) when compared with other cancer types. 
Furthermore, a more extended network connecting ΔNp63α, TP53 and AP-1 transcription 
complexes (among other regulatory hubs), links a larger number of target genes identified in 
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this study by existing experimental data (Figure S10A). Although not all target genes 
identified from our current study are linked by this expanded network (Figure S10A-B), they 
are significantly enriched among the 4213 differentially activated PARADIGM proteins 
inferred between squamous and other cancers (hypergeometric test p = 6E-9 for basal 
targets, and p = 1.22E-10 for TNF-α responsive targets) Table S5.
Discussion
Here we provide evidence for a novel and dynamic genome-wide TF binding paradigm, 
whereby the inflammatory cytokine TNF-α modulated binding activities of cREL, ΔNp63α, 
and TAp73 genome-wide, intersecting a diverse repertoire of genes implicated in the 
malignant phenotype. This modulation was linked to attenuated expression of specific TP53 
tumor suppressor targets and promotion of REL/NF-κB and AP-1 oncogenic and 
inflammatory gene programs (Figure 8). Our study provides a link between global TP63/
TP73, AP-1 and NF-κB mediated survival and inflammatory gene programs, which helps 
explain the finding of unique TP63/TP73 gene signatures compensating for mutant TP53 
identified recently in squamous cancers from TCGA HNSCC and PanCancer projects (1, 2). 
Furthermore, our current data are consistent with previous mechanistic studies 
demonstrating how TNF-α induced changes alter the DNA binding of c-REL, ΔNp63 and 
TAp73 family members (6, 8). Our studies showed that these transcription factors regulate 
genes involved in several aspects of cell fate including cell proliferation, stemness, survival/
apoptosis, and migration, as well as, epithelial cell growth, inflammation and immune 
responses in murine keratinocyte and ΔNp63 transgenic mouse models (27, 28).
After cross comparison of 12 different cancer types, TCGA PanCancer 12 project uncovered 
several unique signatures that differentiate squamous cancers from other cancer types, such 
as high rates of TP53 mutation and TP63 amplification (2). In depth genetic analyses of the 
gene signatures of squamous cancers, revealed attenuated TP53 and increased expression of 
compensatory TP63/TP73 gene signatures. These were not strictly linked with the relatively 
infrequent loss of heterozygosity (LOH) or TP53-truncating loss-of-function mutations, but 
with TP63 amplification and TP63/73 gene expression by PARADIGM-SHIFT analysis 
(23).
Interestingly, our previous experimental results supported a relationship between attenuated 
TP53 target gene expression and partial compensatory function of TP53 family members 
TP63 and/or TP73 in SCC (6, 8). HNSCC with mtTP53 displayed higher ΔNp63 and 
TAp73, and intermediate “compensatory” basal expression of several TP53/TP63/TP73-
regulated apoptotic genes. Expression of these genes was further attenuated by TNF-α, 
DNA binding interaction of cREL with ΔNp63, and displacement of TAp73 (6). In the 
present study, ChIPseq, ChIP PCR, and binding analyses provide evidence for genome-wide 
reprogramming of TAp73 binding to AP-1RE containing promoters, and varying regulation 
of target genes of TP53 as well as AP-1 and REL/NF-κB. Such TP63/TP73 compensatory 
TP53 function has been associated with higher sensitivity to cisplatin chemotherapy in both 
HNSCC (29, 30) and in BRCA1-related triple-negative breast cancer (31), but together with 
promotion of opposing inflammatory and oncogenic gene programs, is apparently 
insufficient to prevent development of these cancers.
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TP53 is highly mutated in HNSCC, ~80-90% in HPV negative tumors, as evident by recent 
TCGA data (1). As we previously reported in the manuscript by Lu et al (6), the increased 
expression of TAp73 is predominantly observed in mtTP53 cell lines, and reduced TAp73 
occupancy is associated with replacement by cREL, not mtTP53 in response to TNF-α. The 
mtTP53 does not co-IP with the cREL/ΔNp63 complex, and is not recruited to CDKN1A 
(p21), NOXA or PUMA promoters by ChIP assay following TNF-α treatment. In addition, 
dependence on cREL and ΔNp63 for TAp73 binding to p21 promoter was shown, whereby 
cREL inversely modulated TAp73 binding. Similar results for TNF-α treatment or cREL 
modulation of TAp73 were obtained in three UM-SCC lines (6). Furthermore, our prior data 
are also consistent with other's evidence for a strong protein interaction is between p63 and 
p73, but not with TP53, because TP53 is lacking the SAM domain at the C-terminal, which 
mediates heterotetramerization between these family members (32, 33).
Our prior and current findings help further clarify the apparent function of TP63/TP73 in 
compensating for TP53 and promoting oncogene expression. First, such compensatory 
activity is associated with enhanced expression of typical TP53 target genes, such as 
CDKN1A (p21) and GADDA45, which control cell cycle (9, 30), as observed in our cell line 
model (Figure 3-5), broader microarray studies of HNSCC tissues (Figure 6B), and 
PanCancer 12 TCGA project (Figure 7). However, TNF-α, cREL, ΔNp63 modulate TAp73, 
attenuating its TP53 compensatory function, while also enhancing a much broader oncogene 
program implicated in cancer promotion (6, 8). This includes growth factor mediated 
signaling, inflammatory cytokines, prosurvival transcription factors such as AP-1 and RELs, 
and anti-apoptotic genes (e.g. CFLAR) (Figure 4-6), which can potentially counter and limit 
compensatory TP53 tumor suppressor function. Secondly, as shown by our and other 
laboratories, as well as in PanCancer 12 project, ΔNp63α is the dominant isoform expressed 
in squamous cancers (2). We and others have shown the strong oncogenic activity of 
ΔNp63α in squamous cancers, including promoting tumor cell proliferation, migration, 
colony formation, and inflammatory responses (8). Thirdly, as our and other laboratories 
previously showed and supported by HNSCC and Pancancer 12 TCGA project, a subset of 
squamous cancers exhibited inflammatory signatures concurrent with TP63/TP73 
compensatory activity (2). Such inflammatory signaling mediated by TNF-α could 
reprogram TP73 tumor suppressor to oncogenic activity, through binding to AP-1 sites, as 
supported by ChIP seq, ChIP RT-PCR, and binding assays (Figure 1-4) in this study. This 
novel finding is also supported by the PanCancer 12 data indicating that inflammatory gene 
signatures linked by cytokine TNF-α and NF-κB transcription factors are connected to TP63 
gene signatures through JUN/FOS mediated pathway and network (Figure 7C and Figure 
S10).
The novel finding from this study of physical interaction among these TFs with genomic 
DNA is supported, among other evidence, by a narrow binding peak within ~200 bp 
surrounding TP53/p63 consensus sites, and a broader peak of ~400-500 bp within which 
nearby AP-1 motifs are distributed. Interestingly, a ~500 bp distance between p73 binding 
and AP-1 sites was independently identified in ChIP-seq experiments in osteosarcoma cells, 
where anti-TAp73α and c-Jun antibodies detected co-binding by ChIP-re-ChIP assay (34). 
In addition, Pietenpol and colleagues identified overlapping AP-1 and p73 binding sites in 
ChIP-seq experiments, and confirmed c-Jun binding within 500 bp of p73 binding sites in 
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rhabdomyosarcoma cells (35). Furthermore, we identified palindromic binding sequences 
for TP53/p63 and AP-1 (Figure 2), which are similar to the sequences of TP53/TP63/TP73 
and nearby AP-1 binding motifs observed in previous studies (34-39). Our study reveals that 
in the absence of TNF-α, TAp73 was mainly bound to TP53/TP63 consensus motifs, 
consistent with that found for growth arrest and pro-apoptotic genes in multiple HNSCC 
lines including UM-SCC46 (6), where TAp73 exhibited a partial compensatory function for 
mutated TP53 (9). However, previous studies have not observed how TNF-α induced 
dynamic alterations of these TF binding activities. After TNF-α treatment, ΔNp63α bound 
at TP53/TP63 sites previously occupied by TAp73, while TAp73 bound to AP-1 sites 
(Figure 2B and D). These dynamic alterations of binding activities reversed TAp73 tumor 
suppressor activity, while increased cREL/ΔNp63α and TAp73 modulated expression of an 
inflammatory and cancer related gene program.
Our previous study demonstrated that TNF-α modulates reciprocal and mutually exclusive 
protein-protein interactions between endogenous nuclear ΔNp63α/TAp73 and cREL/
ΔNp63α complexes (6, 8). Our prior ChIP studies did not resolve if cREL or TAp73 can 
individually bind the same minimal TP53RE, or if TP73 can bind to AP-1 REs independent 
of ΔNp63α or other cofactors. Our sedimentation velocity centrifugation experiments 
revealed that both cREL and TP73 bind these DNA REs and can form dimers and/or 
tetramers upon DNA binding. These results provide biophysical support to the model of co-
localized binding of cREL and TP73 suggested by the ChIP-seq and bioinformatics 
analyses. Collectively, the different experimental approaches provide mechanistic details of 
how TFs can occupy binding sites at the same as well as very close promoter sequences.
Our reporter assays provide evidence for functional overlap in transcriptional activities in 
addition to binding, which demonstrate differing effects of the TFs and TNF-α on 
modulation of transcription (Figure 4A). The reporters contained TP53, AP-1 or NF-κB 
REs. ΔNp63α exhibited minimal effects on TP53, decreased CDKN1A (p21), and 
significantly induced IL-6 expression. This induction was significantly reduced by mutation 
of the NF-κB and AP-1 REs, which is consistent with our and others’ publications (8, 40). 
Significantly, TAp73α strongly induced CDKN1A (p21) and SERPINE1 reporter activity, 
consistent with its compensatory function for mutant TP53 (9, 31, 35, 41, 42), as well as 
induced specific AP-1 promoter activity (43, 44). In addition, reporters with specific TP53 
or AP-1 REs demonstrated the ability of TNF-α to repress TAp73-induced TP53 RE, or 
enhance TAp73-mediated AP-1 RE transactivation, supporting a reciprocal role for TNF-α 
in modulating these response elements.
TNF-α, an inflammatory cytokine produced in the tumor microenvironment of many 
cancers, was previously shown to activate both NF-κB and AP-1 (45, 46), the latter through 
MEK/ERK signaling. These findings are also consistent with the Pan-TCGA data, where the 
Squamous-like cancer type exhibited elevated activity of MAPK signaling pathways (2). 
Here we propose an expanded model, wherein TNF-α modulated TAp73 also appears 
capable of reprogrammed binding of AP1-containing REs, while inducing co-expression of 
AP-1 family member FOSL1/Fra1 and reporters containing AP-1 REs. In addition, FOSL1 
and JUNB expression were significantly associated with p63 and p73 expression in human 
HNSCC cells and ΔNp63α transgenic mice. This is consistent with our finding that FOSL/
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Fra1, cJUN and JUNB are the major AP-1 protein family members expressed and bound to 
AP-1 sites, and which mediate cell proliferation and migration in HNSCC cell lines (47, 48). 
Our data are supported by others’ observations that p73 and AP-1 family members can 
enhance each other's binding and transcription activities (35, 43, 44). Our present study adds 
new evidence that TNF-α is a key factor that induces binding of TAp73 to AP-1 sites and 
increases AP-1 family member transcription, and suggests a new model whereby TNF-α can 
co-modulate AP-1 and reprogram TAp73 to cooperatively activate AP-1 target genes.
Thus, our and others’ studies help explain why when TP53 is mutated or defective in 
function, the TAp73 compensatory function for TP53 is repressed. First, overexpressed 
ΔNp63α is able to form a complex with TAp73 to block its tumor suppressor function (6, 8, 
31). Secondly, TNF-α promotes displacement of TAp73 from pro-apoptotic genes and 
reprograms its binding and activation of AP-1 sites (Figure 2A, 2D, 2E, 3C). Thirdly, 
nuclear TAp73 binding is displaced from TP53/p63 sites by the cREL/ΔNp63α complex as 
supported by experimental validations (Figure 2, 3) (6). Instead, TAp73 function is 
converted to potentiate AP-1 activity and promote survival and inflammatory gene 
expression (Figure 5), as supported by other studies (34, 43). Furthermore, in an independent 
study of a group of genes predicted to be controlled by cJUN/NF-κB (49), 20% of genes 
overlapped with the genes differentially regulated by TAp73 (34).
Together, our current and recent studies (6, 8, 48) reveal a complex, genome-wide 
transcriptional regulatory mechanism whereby TP53, NF-κB and AP-1 family members 
interact to promote a broad signaling network favoring tumor survival and inflammation. 
Our current study helps explain the global mechanisms underlying the newly discovered 
deregulated TP53/p63 network and inflammation, presented recently by TCGA pan-cancer 
project (2), and a study in neuroblastoma (50). The transcriptional regulatory mechanisms 
mediated by TP53, NF-κB and AP-1 family members genome-wide are far more complex 
and nuanced than originally anticipated, and understanding the mechanisms will shed light 
on more effective means for targeting of cancer therapeutics.
Materials and Methods
ChIP and next-generation sequencing (ChIP-seq)
DNA fragments bound by antibodies were prepared following the ChIP protocol using 
sheared DNA (~100-400 bp). The DNA samples were sequenced using a next-generation 
GAIIx sequencer from Illumina following the manufacturer's protocol (San Diego, CA). 
Sequence reads were mapped to the UCSC human genome Hg18 assembly using the Eland 
algorithm (Illumina), permitting up to 2 mismatches and no gaps. Only unique mapped reads 
were used in the binding peak calling analysis. To identify binding peaks, we employed 
MACS (51), in which a dynamic Poisson distribution model was used to detect the 
statistically significant binding peaks in ChIP samples compared to DNA input controls. 
MACS is a widely used algorithm for detection of protein-DNA binding sites when 
analyzing ChIP-seq data. This method is specifically designed to detect the promoter 
transcription factor binding sites, which are typically located within a few hundred DNA 
base pairs. In our study, the default setting was selected, which is commonly utilized and 
suitable to our datasets. Detected peak regions were visualized mainly by using the 
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CisGenome browser (52) together with gene structure, DNA sequences and conservation 
scores. We compared the fraction of peaks residing in various genomic features with the 
corresponding genome background using the CEAS program (53). A binomial test was used 
in this method to obtain the p value of each comparison. Gibbs Sampler (54) was used for 
the de novo motif search for binding site sequences and MEME-ChIP suit (55) was used to 
process the found motifs and compare the results to known motifs in database. Peak 
location, distance to transcriptional start sites (TSSs), peak intersection, motif location and 
intersection analysis were performed using customized python/R scripts. ChIP-seq 
experiments were repeated in UM-SCC46 cell lines, and a representative experiment was 
analyzed and presented in Supplemental Table S1. Minimal background peaks were 
observed in the samples of input DNA or DNA from isotype control antibodies. This study 
utilized the high-performance computational capabilities of the Biowulf Linux cluster at the 
National Institutes of Health, Bethesda, MD (http://biowulf.nih.gov).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. TNF-α promotes genome-wide cREL, p63α and TAp73 binding activities in the 
regulatory regions
(A) UM-SCC46 cells were treated with TNF-α (20 ng/ml) for 1 h to induce altered cREL, 
p63, and p73 protein expression in the nucleus. Oct-1 was used as the loading control. (B) 
ChIP-seq was performed using antibodies against cREL, p63α, and TAp73 for the UM-
SCC46 cells treated (TNF) and untreated (NT) with TNF-α. The pulled-down DNAs were 
sequenced by the high-throughput sequencer GAIIx from Illumina. Total peak numbers (left) 
and peak-bound genes (right) are presented in the bar graph. (C) Characterization of the 
modulation of TF binding in the regulatory regions. The distribution of binding peaks in 
different regions of the genome is presented in the pie charts, and peak numbers are labeled 
at the top. The upper panel shows the percentages of the peaks distributed among regulatory 
(promoter, TTS, intragenic) and intergenic regions. The lower panel shows the percentages 
of the peaks distributed only among the different intragenic regions. (D) The binding peak 
numbers of each TF were plotted within 20 kb upstream (−) and downstream of the TSSs 
across the whole genome. The blue line is the basal transcription factor binding without 
TNF-α treatment; while the green line is after TNF-α treatment. (E) The transcription factor 
binding sites within 1 kb distance were identified, and the number of overlapping sites are 
presented in the Venn diagrams. (F) Distance relationships between two peak sets under 
different conditions in the ChIP-seq experiments were analyzed. Intersected peaks were 
defined to be within 1kb distance on the same chromosome. Y axis shows the quantity of 
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intersected peaks at different intersection distance in bp (x axis). Blue, untreated; green, 
TNF-α treated.
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Figure 2. De novo motif search identified TP53 and AP-1 consensus sequences
The motifs most frequently bound by p63, TAp73 and c-REL transcription factors were 
identified by MEME-ChIP (55) or Gibbs Motif Sampler (54). They are shown as the 
sequence logos with known consensus (A-D left). (A, left) The predominant TP53/p63 
motifs consistent with the TP53.02 consensus sequences were identified in basal binding of 
TAp73. (B, left) The predominant motif of TP63 was identified by TP63α binding activities 
after TNF-α treatment. (C, left) AP-1 motif was identified in basal cREL binding. (D, left) 
The AP-1 motif was observed in TNF-α induced TAp73 binding. (A-D, right) Distance 
relationships between different motifs detected by ChIP-Seq were examined. Motifs are 
considered to be intersecting if they are located within 1 kb distance. The corresponding 
motifs were mapped back to peak sequences. Motif density (y axis) was plotted against the 
distance from the center of the binding peak (x axis), showing the distribution pattern of 
specific motifs in peaks (scales are labeled as ×102). (E) The relative interaction on the TP53 
motif (y axis) was plotted against the distance of basal TAp73 binding vs. TP63α after TNF-
α treatment. Under TNF treated condition, the relative interaction (x axis) of TP63 binding 
on TP53 motifs and TAp73 binding on AP-1 motif was plotted against the distance between 
the two binding motifs (x axis, right). (F) Sedimentation coefficient distribution of purified 
cRel Rel homology domain (RHD, left) and p73 DNA binding domain (DBD, right) binding 
to fluorescein-labeled AP-1 (black), cREL (red) and TP53 (blue) response elements (REs). 
Fluorescein absorbance was detected at 488 nm. The peaks corresponding to the protein 
dimers and tetramers are indicated. No tetrameric binding of p73 DBD was observed to the 
AP-1 and cREL REs. For clarity the peak at 2 S for the unbound DNA species is not 
displayed.
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Figure 3. Validation of co-localized binding activities of cREL, p63α and TAp73
Based on overlapped binding peaks in the regulatory regions, we predicted core binding 
sequences containing potential p63/TP53 or NF-κB/cREL binding motifs using a 
bioinformatics approach. PCR primer sequences were designed to flank the regions 
containing the binding motifs (Table S2). In the genes of interest, the overlapping binding 
peaks were located in promoter/enhancer regions (SERPINE1, BCL3, CEBPA, HBEGF) or 
in first (CDKN1A, FOSL1, TNFSF10) or other (GADD45A) introns. Quantitative PCR was 
performed in independent ChIP experiments, and isotype antibody served as the negative 
control. (A-C) ChIP binding activity of cREL (A), p63α (B), and TAp73 (C). Blue, 
untreated; red, TNF-α treated. (D) The DNA sequences were extracted from ChIP-seq peaks 
and the core p53, p63, AP-1, NF-κB, cREL consensus motifs were predicted and depicted. 
Nuclear extracts were isolated from UM-SCC46 cells and the binding assays were 
performed using a 96-well colorimetric binding assay with 50-70mer oligos containing the 
10-20bp motifs synthesized and labeled with biotin (Table S3). Open bars, anti-p63α 
antibody; dashed bars, anti-TAp73 antibody. Neg: negative control using p21 control oligo 
without lysate. p21-P: positive control using a p21 oligo containing the known TP53/TP63 
site. The data are presented as the mean ± SD calculated from three replicates from one 
representative experiment.
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Figure 4. cREL, ΔNp63α, and TAp73 modulate transcriptional regulation and differential gene 
expression
(A) UM-SCC46 cells were transfected with luciferase reporter plasmids containing specific 
TP53, AP-1, or NF-κB REs (upper panels), or the promoter sequences of CDKN1A (p21) 
(TP53, TP63 REs), SERPINE1 (AP-1 REs) or IL-6 (AP-1 and NF-κB REs; lower panels). 
Overexpression of cREL, ΔNp63α, or TAp73α was induced by TNF-α treatment (20 ng/ml) 
for 48 h. IL-6 binding site-specific point mutant promoter constructs included the deletion 
mutation of NF-κB or AP-1 binding sites without TNF-α (bottom right panel). The relative 
reporter activity was normalized to the corresponding β-gal activity and/or compared with 
the control vectors. Blue, untreated; red, TNF-α treated, except in IL-6 reporter assay 
(bottom right panel). In IL-6 reporter assay without TNF-α treatment, blue: reporter with 
full length IL-6 promoter; red: IL-6 promoter with the NF-κB binding motif deleted; green: 
IL-6 promoter with the AP-1 binding motif deleted. (B) The newly identified target genes 
were validated by q-RT-PCR 48 h after cREL, ΔNp63α, or TAp73α overexpression under 
TNF-α treatment (20 ng/ml). Blue, untreated; red, TNF-α treated. The data are presented as 
the mean ± SD of three replicates from one representative experiment. Statistical 
significance was calculated using a two-tailed Student's T-Test, p<0.05. * indicates the 
statistical significance when comparing the conditions with overexpressed plasmids versus 
control plasmid. # indicates the statistical significance when comparing untreated versus 
TNF-α treated condition.
Si et al. Page 22
Oncogene. Author manuscript; available in PMC 2016 November 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 5. TNF-α modulates expression of a global gene repertoire bound by cREL, p63α, and 
TAp73
RNA was isolated from cells treated with TNF-α for 1, 3, 6, 12, and 24 h and the differential 
gene expression was examined by an Illumina bead-based array. (A) Differential expression 
of up- and down-regulated genes in UM-SCC46 cells under basal level conditions when 
compared with normal human oral keratinocyte cells, and (B) altered gene expression of 
UM-SCC46 cells upon TNF-α treatment. The colored sections represent the percentages of 
differentially expressed genes with binding activities for cREL, p63, or TAp73. (C) Gene 
numbers with individual and intersecting binding activities among the three TFs at the basal 
level, or (D) after TNF-α treatment. Top Venn diagrams represent up-regulated genes, and 
bottom Venn diagrams represent down-regulated genes. (E) Heat maps of hierarchical 
cluster analysis of 46 up-regulated (left) and 27 down-regulated (right) genes with 
overlapped TF binding activities induced by TNF-α. Red, increased expression; blue, 
decreased expression (compared with untreated controls). Color key, Z-score, reflects the 
relationship of the value of gene expression in a specific sample to the mean of the 
expression values of the same gene in all the samples. Euclidean distance with complete 
linkage was used to constitute the gene cluster.
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Figure 6. cREL, ΔNp63, and TAp73 nuclear and cytoplasmic localization and target gene 
expression in human HNSCC tissues and skin of ΔNp63α transgenic mice
(A) 46 up-regulated and 27 down-regulated genes from Figure 5D were queried using the 
mRNA expression dataset from TCGA HNSCC project, which includes 279 tumor and 16 
mucosa specimens. Significant up-regulation of 13/46 activated genes (red), and down-
regulation of 10/27 repressed genes (blue) are detected in TCGA tumors compared to 
normal samples (fold change ≥1.5, student t-Test with FDR < 1% multivariate comparison 
correction cut off). (B) Three publicly available datasets of gene profiling microarrays were 
investigated, which included a total of 125 (67 metastatic and 58 non-metastatic) HNSCC 
tissues. Pearson correlation coefficients of gene expression between p63 and potential target 
genes were calculated, and genes exhibiting statistically significant correlation are presented. 
The line indicates p<0.05. (C) RNA was isolated from the skins of ΔNp63α transgenic mice 
(red). qRT-PCR was performed to quantify gene expression levels with a statistically 
significant increase compared with their age-matched non-transgenic littermates (blue, 
p<0.05). The data were calculated from triplicates of one representative experiment and 
presented as the mean ± SD. (D) Human HNSCC and normal mucosa frozen sections were 
stained for cREL, ΔNp63, and TAp73, and intensities within nuclei or cytoplasm in three 
200X fields per slide were acquired and quantified using an Aperio Scanscope and Cell 
Quantification Software (Vista, CA, USA), and presented as mean histoscores ± SD for 8-13 
samples. * p<0.05, HNSCC vs normal mucosa by t-tests. (E) Immunohistochemistry 
comparing transcription factors JUNB and FOSL1 nuclear staining in human HNSCC tissue 
array. Images were acquired using an Aperio Scanscope at 200X magnification, and staining 
intensity was quantified using Aperio Cell Quantification Software. Tumor protein 
expression of evaluable specimens for JUNB and FOSL1 (n=66) and mucosa (n=11) 
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samples. Student t-test, p<0.05 (F) Associations in expression levels between the 
transcription factors nuclear cREL with targets nuclear JUNB and IKKε (stage III tumors), 
nuclear cREL with nuclear FOSL1 (in all tumor stages), and nuclear TP63 with nuclear 
SERPINE1/PAI1 (metastatic tumors). A non-directional test for the significance of the 
Pearson Product-Moment Correlation Coefficient with the computed histoscores for each 
protein was used.
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Figure 7. Squamous cancer signatures by CircleMaps and PARADIGM SuperPathway analyses
(A) CircleMap of PARADIGM-Shift differences associated with SCC tissue origins and 
TP53 mutation status were created for TP53, TP63, TP73 and target genes identified in this 
study. Samples were ordered first by tissue origin of SCC (innermost ring), then by TP53 
mutation status (second ring), GISTIC score (indicating CNV), mRNA expression level, and 
finally by PARADIGM activities (outer ring). The Red-blue color intensity reflects 
magnitude of CNV, expression and PARADIGM activities (red: high, blue: low). TP53 
mutation is highlighted (black: truncation, gray: missense). Samples were restricted to the 
C2-Squamous-like cluster-of-cluster-assignments (COCA), including 156 lung SSC, 293 
HNSCC, and 24 bladder SCC samples. Each plot illustrates multiple data types across many 
samples for a given gene. (B) The PARADIGM activity of ΔNp63 or TP73, and expression 
of eight target genes are higher across SCC tumors compared with other cancer types as 
shown in (A). Pearson correlation coefficients between ΔNp63 or TP73 PARADIGM 
activity and eight target genes presented in (A) were calculated, and the significance of p 
value was presented in y axis. The PARADIGM activity of ΔNp63 exhibited significant 
positive correlations with expression of five target genes bound and inducible by TNF-α, 
and a negative correlation with CEBPA expression. The PARADIGM activity of TP73 
exhibited negative associations with with IL-6 and SERPINE1, and a positive association 
with CDKN1A (p21). (C) PARADIGM SuperPathway subnetwork defining C2-Squamous-
like Pan-Cancer 12 integrative subtype. Zoom-in view of network neighborhood surrounding 
the ΔNp63α tetramer, TAp63γ tetramer, RelA/p50 and Jun/Fos complexes. Color of the 
nodes reflects activation (red) or repression (blue) within the squamous subtype when 
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compared with the mean of other tumor types. Edge color denotes interaction type: 
inhibitory (green) and activating (yellow). Node shape reflects feature type: protein (circle), 
complex (diamond), family or miRNA or RNA (square), abstract concepts (arrowhead). The 
target genes with cRel, p63 and TAp73 binding identified in this study are highlighted with 
different colored outer rings as showing in supplemental Figure S10.
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Figure 8. Mechanistic model illustrating effects of TNF-α modulation of cREL, ΔNp63α and 
TAp73 chromatin occupancy and reprogramming of TAp73 from TP53 to AP-1 sites to promote 
inflammatory and cancer gene programs
Most head and neck and solid cancers have high frequencies of TP53 mutation, where 
TAp73 can serve as a potential tumor suppressor. In this model, without TNF-α, TAp73 
predominantly occupies TP53 or p63 binding sites, while NF-κB family member cREL 
either resides in the cytoplasm or in the nucleus with binding on AP-1 sites, and ΔNp63α is 
found in the nucleus unbound to DNA (upper left). TNF-α, a major inflammatory cytokine 
produced in the tumor microenvironment, can promote cREL nuclear translocation, and 
complexes with ΔNp63α, to occupy TP53/p63 binding sites. TNF-α also induces nuclear 
displacement or reprogramming of TAp73 to bind neighboring AP-1 sites (upper and bottom 
right). These dynamic alterations diminish TAp73 tumor suppressor activity, while 
enhancing cREL/ΔNp63α and TAp73 mediated inflammatory and cancer gene programs 
(lower left). This model helps explains how TNF-α modulates NF-κB and AP-1 signaling 
while altering tumor suppressor activity, to promote gene programs implicated in 
inflammation, survival, and metastasis.
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